GCG and metabolic dysfunction-associated steatohepatitis: Several clinical trials have been performed to study the effect of GLP-1 RAs on NAFDL and NASH since 2007, most of which concerned the determination of the role of these drugs in NAFLD and recruited individuals with pre-existing T2DM.